Analyst Viewpoint
Extensive research in treatment of Respiratory Syncytial Virus (RSV) infections and growth in incidence of RSV infections are primary factors augmenting the global Respiratory Syncytial Virus therapeutics market revenue.
RSV causes respiratory disorders, with infants and the aging population at higher risk of contraction. Research regarding therapeutics (vaccines and drugs) began in 1960s; however, just one to two medications stand approved as of now.
Presence of several drugs under clinical trials and approvals is also fostering Respiratory Syncytial Virus therapeutics industry development.
Respiratory Syncytial Virus therapeutics market manufacturers are striving to introduce combined medications – orally administered as well as injectable drugs – for RSV infections. Significant unmet need for innovative RSV therapeutics for infants has created lucrative Respiratory Syncytial Virus Therapeutics business opportunities for companies operating in the sector.
Respiratory Syncytial Virus (RSV) is a type of respiratory virus that primarily affects infants and young children, and also the geriatric population. Those with weaker immune systems are also at higher risk of contracting RSV infection.
RSV therapeutics and drugs operate by inhibiting the replication of the virus, thereby reducing duration of the illness and its severity. Research is underway regarding development of monoclonal antibodies (mAbs). These are being designed for binding to specific viral cells or proteins for blocking the viral entry or promoting clearance of virus by the immune system.
Various vaccine candidates including subunit, live attenuated, and nanoparticle-based vaccines are under clinical development. With the exception of a vaccine approved in 2023, the other modes of treatment as well as vaccines are at the nascent stage of development.
The time taken from conceptualization to approval of therapeutics for RSV is quite long. This is a key factor that is hampering the Respiratory Syncytial Virus therapeutics market size to a certain extent.
RSV is a complex virus that presents challenges with regards to understanding pathogenesis, immune response, and the probable therapeutic targets. Several pharmaceutical firms are experiencing challenges regarding development of medications for RSV infection.
SYNAGIS (palivizumab) is the only medication approved in the last 20 years, with the recent breakthrough being Arexvy (vaccine) from GlaxoSmithKline. There is immense scope for emerging antiviral drugs for RSV infection in the RSV antiviral medications market, as their approval would provide patients access to a sizable number of medications.
Several drugs are in pipeline for trials and approvals from regulatory bodies such as the US FDA. Thus, the Respiratory Syncytial Virus therapeutics market forecast appears promising owing to the efforts of companies to introduce drugs and therapies for RSV infections.
Human respiratory syncytial virus is one of the common causes of lower respiratory tract infections in people of all age groups. In those aged six and below, the first infection may result in bronchiolitis, which could prove fatal at times.
In those aged between six and 60 (especially the ones without comorbidities), repeated upper respiratory tract infections are observed, which range between subclinical infection and symptomatic upper respiratory tract disease.
For individuals aged 60 and above, the risk of severe RSV infection increases with the occurrence of underlying chronic pulmonary disease, functional disability, and circulatory conditions. Those who have undergone lung or bone marrow transplantation are also more prone to the RSV disease.
As per the International Journal of Infectious Diseases, mortality is the highest in children aged five and below and the elderly aged above 65. UNICEF states that approximately 650 million of the global population comprises children aged five and below, while the World Bank states that 10% of the same global population comprises those aged 65 and above.
Thus, rise in incidence of RSV infections across the globe is a prominent factor that is propelling market statistics.
North America accounted for the largest Respiratory Syncytial Virus therapeutics market share in 2022. The region is projected to maintain its dominance across the globe during the forecast period.
High share of North America can be ascribed to the rise in incidence of RSV infections in the region. As per the Center for Disease Control and Prevention, RSV infection alone results in 2.4 million outpatient visits among those aged below five in the U.S. Thus, the RSV treatment market is likely to grow substantially in the region in the near future.
Asia Pacific is expected to record significant market expansion during the forecast period. Presence of sophisticated healthcare infrastructure in Australia and Japan is driving the Respiratory Syncytial Virus therapeutics industry in the region.
On the other hand, countries such as India and China are striving to increase awareness regarding RSV infection and treatments among millennials. In 2023, the Beijing Center for Disease Prevention and Control unveiled the Beijing Major Respiratory Epidemic Disease Center with the objective of advancing its understanding of transmission of disease, diagnostic methods, proper control strategies, and various early warning symptoms.
Companies operating in the global Respiratory Syncytial Virus therapeutics market are conducting clinical trials regarding RSV therapeutics. For instance, in March 2022, AstraZeneca, during MEDLEY Phase 2/3 study, reported plausible tolerance and safety findings for a long-acting antibody medication called nirsevimab (a long-acting antibody medication that is especially deigned to treat babies at a higher risk of RSV infection).
The Respiratory Syncytial Virus therapeutics market report highlights prominent companies such as F. Hoffmann-La Roche Ltd., AstraZeneca plc, Merck & Co., Inc., AbbVie, Inc., Valeant Pharmaceuticals International, Inc., GlaxoSmithKline plc, ReViral Ltd., Gilead Sciences, Inc., Medivir AB, and Teva Pharmaceuticals Industries Ltd. based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 1.1 Bn |
| Market Forecast (Value) in 2031 | US$ 3.8 Bn |
| Market Growth Rate (CAGR) | 14.6% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 1.1 Bn in 2022
It is projected to advance at a CAGR of 14.6% from 2023 to 2031
Extensive research in treatment of RSV infections and growth in incidence of RSV infections
The drug stores and retail pharmacies segment accounted for the largest share in 2022
North America was the dominant region in 2022
F. Hoffmann-La Roche Ltd., AstraZeneca plc, Merck 7 Co., Inc., AbbVie, Inc., Valeant Pharmaceuticals International, Inc., GlaxoSmithKline plc, ReViral Ltd., Gilead Sciences, Inc., Medivir AB, and Teva Pharmaceuticals Industries Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Respiratory Syncytial Virus (RSV) Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Type, 2017–2031
6.3.1. Palivizumab
6.3.2. Ribavirin
6.3.3. Others
6.4. Market Attractiveness Analysis, by Drug Type
7. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast, by Dosage Form
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Dosage Form, 2017–2031
7.3.1. Oral
7.3.2. Injectable
7.3.3. Others
7.4. Market Attractiveness Analysis, by Dosage Form
8. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Drug Stores and Retail Pharmacies
8.3.2. Hospital Pharmacies
8.3.3. Others
8.4. Market Attractiveness Analysis, by Dosage Form
9. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Type, 2017–2031
10.3.1. Palivizumab
10.3.2. Ribavirin
10.3.3. Others
10.4. Market Value Forecast, by Dosage Form, 2017–2031
10.4.1. Oral
10.4.2. Injectable
10.4.3. Others
10.5. Market Value Forecast, by Distribution Channel, 2017–2031
10.5.1. Drug Stores and Retail Pharmacies
10.5.2. Hospital Pharmacies
10.5.3. Others
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Drug Type
10.7.2. By Dosage Form
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Type, 2017–2031
11.3.1. Palivizumab
11.3.2. Ribavirin
11.3.3. Others
11.4. Market Value Forecast, by Dosage Form, 2017–2031
11.4.1. Oral
11.4.2. Injectable
11.4.3. Others
11.5. Market Value Forecast, by Distribution Channel, 2017–2031
11.5.1. Drug Stores and Retail Pharmacies
11.5.2. Hospital Pharmacies
11.5.3. Others
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Drug Type
11.7.2. By Dosage Form
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Type, 2017–2031
12.3.1. Palivizumab
12.3.2. Ribavirin
12.3.3. Others
12.4. Market Value Forecast, by Dosage Form, 2017–2031
12.4.1. Oral
12.4.2. Injectable
12.4.3. Others
12.5. Market Value Forecast, by Distribution Channel, 2017–2031
12.5.1. Drug Stores and Retail Pharmacies
12.5.2. Hospital Pharmacies
12.5.3. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Drug Type
12.7.2. By Dosage Form
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Type, 2017–2031
13.3.1. Palivizumab
13.3.2. Ribavirin
13.3.3. Others
13.4. Market Value Forecast, by Dosage Form, 2017–2031
13.4.1. Oral
13.4.2. Injectable
13.4.3. Others
13.5. Market Value Forecast, by Distribution Channel, 2017–2031
13.5.1. Drug Stores and Retail Pharmacies
13.5.2. Hospital Pharmacies
13.5.3. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Drug Type
13.7.2. By Dosage Form
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Drug Type, 2017–2031
14.3.1. Palivizumab
14.3.2. Ribavirin
14.3.3. Others
14.4. Market Value Forecast, by Dosage Form, 2017–2031
14.4.1. Oral
14.4.2. Injectable
14.4.3. Others
14.5. Market Value Forecast, by Distribution Channel, 2017–2031
14.5.1. Drug Stores and Retail Pharmacies
14.5.2. Hospital Pharmacies
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Drug Type
14.7.2. By Dosage Form
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. F. Hoffmann-La Roche Ltd.
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. AstraZeneca plc
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Merck & Co., Inc.
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. AbbVie, Inc.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Valeant Pharmaceuticals International, Inc.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. GlaxoSmithKline plc
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. ReViral Ltd.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Gilead Sciences, Inc.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Medivir AB
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Teva Pharmaceuticals Industries Ltd.
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
List of Tables
Table 01: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 02: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 03: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 07: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 08: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 09: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 11: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 12: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 15: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 16: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 17: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 19: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 20: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 23: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 24: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) and Distribution (%), by Region, 2022–2031
Figure 02: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (US$ Mn), by Drug Type, 2022
Figure 03: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Drug Type, 2022
Figure 04: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (US$ Mn), by Dosage Form, 2022
Figure 05: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Dosage Form, 2022
Figure 06: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (US$ Mn), by Distribution Channel, 2022
Figure 07: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Distribution Channel, 2022
Figure 08: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Region, 2022
Figure 09: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value (US$ Mn) Forecast, 2023–2031
Figure 10: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Drug Type, 2022–2031
Figure 11: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 12: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Dosage Form, 2022–2031
Figure 13: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Dosage Form, 2023–2031
Figure 14: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 15: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 16: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Region, 2022–2031
Figure 17: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Region, 2023–2031
Figure 18: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 19: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Country, 2023–2031
Figure 20: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Country, 2022–2031
Figure 21: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Drug Type, 2022–2031
Figure 22: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Dosage Form, 2022–2031
Figure 23: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 24: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 25: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Dosage Form, 2023–2031
Figure 26: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 27: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 28: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 29: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 30: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Drug Type, 2022–2031
Figure 31: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Dosage Form, 2022–2031
Figure 32: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 33: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 34: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Dosage Form, 2023–2031
Figure 35: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 36: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 37: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 38: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 39: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Drug Type, 2022–2031
Figure 40: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Dosage Form, 2022–2031
Figure 41: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 42: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 43: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Dosage Form, 2023–2031
Figure 44: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 45: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 46: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 47: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 48: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Drug Type, 2022–2031
Figure 49: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Dosage Form, 2022–2031
Figure 50: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 51: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 52: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Dosage Form, 2023–2031
Figure 53: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 54: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 55: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 56: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 57: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Drug Type, 2022–2031
Figure 58: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Dosage Form, 2022–2031
Figure 59: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 60: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 61: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Dosage Form, 2023–2031
Figure 62: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Respiratory Syncytial Virus Therapeutics Market
